A RANDOMIZED TRIAL OF CISPLATIN (CACP) + 5-FLUOROURACIL (5-FU) INFUSION AND CACP + 5-FU BOLUS FOR RECURRENT AND ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

被引：0
|
作者：
KISH, JA
ENSLEY, JF
JACOBS, J
WEAVER, A
CUMMINGS, G
ALSARRAF, M
机构：
[1] WAYNE STATE UNIV,HARPER GRACE HOSP,DIV ONCOL,DETROIT,MI 48201
[2] WAYNE STATE UNIV,HARPER GRACE HOSP,DEPT OTOLARYNGOL,DETROIT,MI 48201
[3] WAYNE STATE UNIV,HARPER GRACE HOSP,DEPT SURG,DETROIT,MI 48201
[4] VET ADM MED CTR,ALLEN PK,MI 48101
来源：
CANCER | 1985年 / 56卷 / 12期
关键词：
D O I：
10.1002/1097-0142(19851215)56:12<2740::AID-CNCR2820561203>3.0.CO;2-Y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2740 / 2744
页数：5
相关论文
共 50 条
  • [21] Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Humblet, Y
    Vega-Villegas, E
    Mesia, R
    Awada, A
    Geoffrois, L
    Borel, C
    Hitt, R
    Amellal, N
    Bessa, EH
    Bourhis, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 491S - 491S
  • [22] 5-fluorouracil (5-FU) plasma exposure and outcome in patients receiving a TPF (taxotere, cisplatin, 5-FU) chemotherapy
    Legand, C.
    Blasco, H.
    Benz, I.
    Chapet, C.
    Le Guellec, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 25 - 25
  • [23] ESCALATING BOLUS DOSE 5-FLUOROURACIL (5-FU) FOR METASTATIC COLORECTAL-CARCINOMA
    MAYER, RJ
    STEELE, GD
    FREI, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 415 - 415
  • [24] Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells
    Ijichi, Kei
    Adachi, Makoto
    Hasegawa, Yasuhisa
    Ogawa, Tetsuya
    Nakamura, Hideaki
    Kudoh, Ayumi
    Yasui, Yoshihiro
    Murakami, Shingo
    Ishizaki, Kanji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 745 - 752
  • [25] Phase II clinical trial of cisplatin (CDDP), 5-Fluorouracil (5-FU) and ifosfamide (IFX) as treatment for advanced locoregional head and neck carcinoma (AHNC)
    Parra, MS
    Churruca, C
    Paredes, A
    Lacasta, A
    de Argumedo, GL
    Alvarez, I
    Abad, T
    Egana, L
    Iriarte, L
    Urraca, JM
    Piera, JM
    ANNALS OF ONCOLOGY, 1998, 9 : 79 - 79
  • [26] 5-FLUOROURACIL (5-FU) PRESENTING AS A STEMI
    Okor, Ivana
    Ghosh, Priyanka
    Bhattarai, Shraddha
    Sattur, Sudhakar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 3439 - 3439
  • [27] RANDOMIZED TRIAL OF MELPHALAN PLUS 5-FLUOROURACIL (5-FU) VERSUS METHYL-CCNU PLUS 5-FU IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    BERMAN, R
    GILES, GR
    MALHOTRA, A
    BIRD, GG
    GAJJAR, PD
    BUNCH, GA
    HALL, R
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 457 - 459
  • [28] Photosensitivity due to 5-fluorouracil (5-FU)
    von Moos, R
    Sauter, C
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 129 (1-2) : 52 - 52
  • [29] CHEMOTHERAPY OF RECURRENT SQUAMOUS CARCINOMA OF THE HEAD AND NECK WITH CISPLATIN ADRIAMYCIN (DDP/ADM) AND METHOTREXATE 5-FLUOROURACIL (MTX/5-FU) - A RETROSPECTIVE COMPARISON OF 2 PROTOCOLS
    JAKSE, R
    SCHERLACHER, A
    LEHNERT, M
    HAAS, J
    HNO, 1986, 34 (06) : 235 - 240
  • [30] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
12345